 In this study, it was found that laflunamide was effective in treating BK virus reactivation in kidney and kidney pancreas transplant recipients. However, the majority of patients required higher doses than the standard 40 mg daily dose to reach therapeutic levels and clear the virus. Additionally, delaying treatment with laflunamide could lead to progression of BK virus reactivation and BK nephropathy. This article was authored by Nicole Nestelhoff, Jacqueline Strutt and Bahar Bastani.